Diversify Advisory Services LLC Makes New Investment in Boston Scientific Corporation $BSX

Diversify Advisory Services LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 15,146 shares of the medical equipment provider’s stock, valued at approximately $689,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Renaissance Group LLC acquired a new position in Boston Scientific during the 4th quarter worth about $28,064,000. Perigon Wealth Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at about $883,000. Y Intercept Hong Kong Ltd increased its stake in Boston Scientific by 148.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock worth $13,659,000 after purchasing an additional 28,961 shares during the period. Finally, Meiji Yasuda America Inc acquired a new stake in shares of Boston Scientific during the fourth quarter worth about $4,708,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 4.9%

BSX stock opened at $49.47 on Friday. The company’s 50 day moving average price is $46.26 and its 200 day moving average price is $57.91. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The firm has a market capitalization of $71.69 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 1.13 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter last year, the company earned $0.75 earnings per share. The firm’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently commented on BSX. Bank of America lowered their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Wells Fargo & Company reduced their target price on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a report on Thursday, July 30th. UBS Group decreased their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Evercore set a $65.00 price target on shares of Boston Scientific in a research note on Monday, July 6th. Finally, Mizuho cut their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.